Overview

Clinical Trial to Determine the MTD of HM781-36B in Patients With Advanced Solid Tumors

Status:
Completed
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
The main objective of this study is to determine the maximum tolerated dose (MTD) of HM781-36B continuously.
Phase:
Phase 1
Details
Lead Sponsor:
Hanmi Pharmaceutical Company Limited